Laboratory Medicine ›› 2024, Vol. 39 ›› Issue (2): 155-160.DOI: 10.3969/j.issn.1673-8640.2024.02.010
Previous Articles Next Articles
SONG Xiaolong, QIN Jinlü, YANG Ru, WEI Long, ZHOU Jianping()
Received:
2022-11-30
Revised:
2023-10-29
Online:
2024-02-28
Published:
2024-03-26
Contact:
ZHOU Jianping
CLC Number:
SONG Xiaolong, QIN Jinlü, YANG Ru, WEI Long, ZHOU Jianping. Application of serum TK1 in postoperative monitoring of thyroid papillary carcinoma patients[J]. Laboratory Medicine, 2024, 39(2): 155-160.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2024.02.010
组别 | 例数 | 性别 | 年龄(岁) | 肿瘤多灶性/ [例(%)] | 肿瘤最大直径 | |||
---|---|---|---|---|---|---|---|---|
男/ [例(%)] | 女/ [例(%)] | <55岁/ [例(%)] | ≥55岁/ [例(%)] | ≤10 mm/ [例(%)] | >10 mm/ [例(%)] | |||
ER组 | 153 | 26(17.0) | 127(83.0) | 125(81.7) | 28(18.3) | 61(40.0) | 83(54.2) | 70(45.8) |
NER组 | 25 | 7(28.0) | 18(72.0) | 11(44.0) | 14(56.0)* | 17(68.0)* | 6(24.0) | 19(76.0)* |
组别 | T 分期 | N 分期 | ||||||
T1期/[例(%)] | T2期/[例(%)] | T3期/[例(%)] | N0期/[例(%)] | N1a期/[例(%)] | N1b期/[例(%)] | |||
ER组 | 115(75.2) | 27(17.6) | 11(7.2) | 53(34.6) | 57(37.3) | 43(28.1) | ||
NER组 | 1(4.0) | 6(24.0) | 18(72.0)* | 0(0.0) | 12(48.0) | 13(52.0)* | ||
组别 | 转移淋巴结数 | 治疗方式 | 被膜侵犯/ [例(%)] | |||||
< 3个/ [例(%)] | 3~5个/ [例(%)] | >5个/ [例(%)] | 次全切/ [例(%)] | 全切/ [例(%)] | 全切+131I/ [例(%)] | |||
ER组 | 87(56.9) | 31(20.3) | 35(22.9) | 45(29.4) | 51(33.3) | 57(37.3) | 91(59.5) | |
NER组 | 5(20.0) | 10(40.0) | 10(40.0)* | 8(32.0) | 11(44.0) | 6(24.0) | 17(68.0) |
组别 | 例数 | 性别 | 年龄(岁) | 肿瘤多灶性/ [例(%)] | 肿瘤最大直径 | |||
---|---|---|---|---|---|---|---|---|
男/ [例(%)] | 女/ [例(%)] | <55岁/ [例(%)] | ≥55岁/ [例(%)] | ≤10 mm/ [例(%)] | >10 mm/ [例(%)] | |||
ER组 | 153 | 26(17.0) | 127(83.0) | 125(81.7) | 28(18.3) | 61(40.0) | 83(54.2) | 70(45.8) |
NER组 | 25 | 7(28.0) | 18(72.0) | 11(44.0) | 14(56.0)* | 17(68.0)* | 6(24.0) | 19(76.0)* |
组别 | T 分期 | N 分期 | ||||||
T1期/[例(%)] | T2期/[例(%)] | T3期/[例(%)] | N0期/[例(%)] | N1a期/[例(%)] | N1b期/[例(%)] | |||
ER组 | 115(75.2) | 27(17.6) | 11(7.2) | 53(34.6) | 57(37.3) | 43(28.1) | ||
NER组 | 1(4.0) | 6(24.0) | 18(72.0)* | 0(0.0) | 12(48.0) | 13(52.0)* | ||
组别 | 转移淋巴结数 | 治疗方式 | 被膜侵犯/ [例(%)] | |||||
< 3个/ [例(%)] | 3~5个/ [例(%)] | >5个/ [例(%)] | 次全切/ [例(%)] | 全切/ [例(%)] | 全切+131I/ [例(%)] | |||
ER组 | 87(56.9) | 31(20.3) | 35(22.9) | 45(29.4) | 51(33.3) | 57(37.3) | 91(59.5) | |
NER组 | 5(20.0) | 10(40.0) | 10(40.0)* | 8(32.0) | 11(44.0) | 6(24.0) | 17(68.0) |
组别 | 例数 | 术前/(pmol·L-1) | 术后 | |||
---|---|---|---|---|---|---|
1个月/(pmol·L-1) | 3个月/(pmol·L-1) | 6个月/(pmol·L-1) | 12个月/(pmol·L-1) | |||
ER组 | 153 | 2.31(2.05~2.69) | 1.03(0.69~1.51) | 0.69(0.47~0.92) | 0.51(0.30~0.67) | 0.34(0.21~0.52) |
NER组 | 25 | 2.38(2.18~2.74) | 1.51(1.09~1.85)* | 0.96(0.80~1.07)* | 0.87(0.61~1.01)* | 0.89(0.54~1.04)* |
组别 | 例数 | 术前/(pmol·L-1) | 术后 | |||
---|---|---|---|---|---|---|
1个月/(pmol·L-1) | 3个月/(pmol·L-1) | 6个月/(pmol·L-1) | 12个月/(pmol·L-1) | |||
ER组 | 153 | 2.31(2.05~2.69) | 1.03(0.69~1.51) | 0.69(0.47~0.92) | 0.51(0.30~0.67) | 0.34(0.21~0.52) |
NER组 | 25 | 2.38(2.18~2.74) | 1.51(1.09~1.85)* | 0.96(0.80~1.07)* | 0.87(0.61~1.01)* | 0.89(0.54~1.04)* |
组别 | 例数 | 术前/(pmol·L-1) | 术后 | |||
---|---|---|---|---|---|---|
1个月/(pmol·L-1) | 3个月/(pmol·L-1) | 6个月/(pmol·L-1) | 12个月/(pmol·L-1) | |||
次全切组 | ||||||
ER | 45 | 2.31(2.01~2.49) | 1.14(0.73~1.54) | 0.69(0.46~0.89) | 0.54(0.28~0.65) | 0.31(0.25~0.44) |
NER | 8 | 2.42(2.23~2.54) | 1.56(0.89~2.06) | 0.94(0.77~1.02)* | 1.00(0.65~1.03)* | 0.97(0.90~1.22)* |
全切组 | ||||||
ER | 108 | 2.30(2.11~2.81) | 1.03(0.69~1.44) | 0.69(0.49~0.94) | 0.51(0.21~0.67) | 0.31(0.18~0.42) |
NER | 17 | 2.35(2.08~2.77) | 1.51(1.09~1.85)* | 0.96(0.84~1.12)* | 0.77(0.58~0.96)* | 0.78(0.51~0.93)* |
组别 | 例数 | 术前/(pmol·L-1) | 术后 | |||
---|---|---|---|---|---|---|
1个月/(pmol·L-1) | 3个月/(pmol·L-1) | 6个月/(pmol·L-1) | 12个月/(pmol·L-1) | |||
次全切组 | ||||||
ER | 45 | 2.31(2.01~2.49) | 1.14(0.73~1.54) | 0.69(0.46~0.89) | 0.54(0.28~0.65) | 0.31(0.25~0.44) |
NER | 8 | 2.42(2.23~2.54) | 1.56(0.89~2.06) | 0.94(0.77~1.02)* | 1.00(0.65~1.03)* | 0.97(0.90~1.22)* |
全切组 | ||||||
ER | 108 | 2.30(2.11~2.81) | 1.03(0.69~1.44) | 0.69(0.49~0.94) | 0.51(0.21~0.67) | 0.31(0.18~0.42) |
NER | 17 | 2.35(2.08~2.77) | 1.51(1.09~1.85)* | 0.96(0.84~1.12)* | 0.77(0.58~0.96)* | 0.78(0.51~0.93)* |
组别 | 例数 | 术前/(μg·L-1) | 术后 | |||
---|---|---|---|---|---|---|
1个月/(μg·L-1) | 3个月/(μg·L-1) | 6个月/(μg·L-1) | 12个月/(μg·L-1) | |||
ER组 | 108 | 31.10(18.72~56.87) | 2.84(0.49~7.66) | 0.79(0.24~2.72) | 0.41(0.18~0.95) | 0.18(0.08~0.31) |
NER组 | 17 | 101.70(25.72~145.73)* | 8.54(4.37~19.23)* | 5.14(2.45~5.23)* | 3.17(1.97~4.35)* | 1.04(0.71~1.32)* |
组别 | 例数 | 术前/(μg·L-1) | 术后 | |||
---|---|---|---|---|---|---|
1个月/(μg·L-1) | 3个月/(μg·L-1) | 6个月/(μg·L-1) | 12个月/(μg·L-1) | |||
ER组 | 108 | 31.10(18.72~56.87) | 2.84(0.49~7.66) | 0.79(0.24~2.72) | 0.41(0.18~0.95) | 0.18(0.08~0.31) |
NER组 | 17 | 101.70(25.72~145.73)* | 8.54(4.37~19.23)* | 5.14(2.45~5.23)* | 3.17(1.97~4.35)* | 1.04(0.71~1.32)* |
项目 | AUC(95%CI①) | 最佳临界值/(pmol·L-1) | P值 | 敏感性/% | 特异性/% |
---|---|---|---|---|---|
术前 | 0.617(0.418~0.815) | 2.18 | 0.297 | 87.5 | 46.7 |
术后1个月 | 0.674(0.462~0.885) | 1.58 | 0.120 | 50.0 | 82.2 |
术后3个月 | 0.760(0.599~0.921) | 0.76 | 0.020 | 87.5 | 62.2 |
术后6个月 | 0.835(0.670~0.999) | 0.75 | 0.003 | 75.0 | 93.3 |
术后12个月 | 0.940(0.852~0.999) | 0.57 | <0.001 | 87.5 | 93.3 |
项目 | AUC(95%CI①) | 最佳临界值/(pmol·L-1) | P值 | 敏感性/% | 特异性/% |
---|---|---|---|---|---|
术前 | 0.617(0.418~0.815) | 2.18 | 0.297 | 87.5 | 46.7 |
术后1个月 | 0.674(0.462~0.885) | 1.58 | 0.120 | 50.0 | 82.2 |
术后3个月 | 0.760(0.599~0.921) | 0.76 | 0.020 | 87.5 | 62.2 |
术后6个月 | 0.835(0.670~0.999) | 0.75 | 0.003 | 75.0 | 93.3 |
术后12个月 | 0.940(0.852~0.999) | 0.57 | <0.001 | 87.5 | 93.3 |
项目 | AUC(95%CI) | 最佳临界值 | P值 | 敏感性/% | 特异性/% |
---|---|---|---|---|---|
TK1 | |||||
术前 | 0.493(0.360~0.625) | 0.552 | |||
术后1个月 | 0.708(0.582~0.834) | 1.30 pmol·L-1 | 0.006 | 70.6 | 70.4 |
术后3个月 | 0.755(0.650~0.861) | 0.80 pmol·L-1 | 0.001 | 82.4 | 59.3 |
术后6个月 | 0.775(0.664~0.886) | 0.69 pmol·L-1 | <0.001 | 64.7 | 82.4 |
术后12个月 | 0.902(0.835~0.968) | 0.68 pmol·L-1 | <0.001 | 64.7 | 95.4 |
Tg | |||||
术前 | 0.741(0.606~0.876) | 62.08 μg·L-1 | 0.001 | 70.6 | 78.7 |
术后1个月 | 0.779(0.668~0.889) | 5.48 μg·L-1 | <0.001 | 76.5 | 67.6 |
术后3个月 | 0.799(0.698~0.889) | 2.24 μg·L-1 | <0.001 | 88.2 | 73.1 |
术后6个月 | 0.926(0.823~0.995) | 1.44 μg·L-1 | <0.001 | 88.2 | 86.1 |
术后12个月 | 0.953(0.891~0.996) | 1.02 μg·L-1 | <0.001 | 94.1 | 85.2 |
项目 | AUC(95%CI) | 最佳临界值 | P值 | 敏感性/% | 特异性/% |
TK1+Tg | |||||
术后1个月 | 0.780(0.627~0.934) | 0.298 | <0.001 | 70.6 | 92.6 |
术后3个月 | 0.885(0.812~0.959) | 0.340 | <0.001 | 88.2 | 73.1 |
术后6个月 | 0.934(0.855~0.999) | 0.211 | <0.001 | 94.1 | 81.5 |
术后12个月 | 0.964(0.933~0.995) | 0.213 | <0.001 | 94.1 | 87.0 |
项目 | AUC(95%CI) | 最佳临界值 | P值 | 敏感性/% | 特异性/% |
---|---|---|---|---|---|
TK1 | |||||
术前 | 0.493(0.360~0.625) | 0.552 | |||
术后1个月 | 0.708(0.582~0.834) | 1.30 pmol·L-1 | 0.006 | 70.6 | 70.4 |
术后3个月 | 0.755(0.650~0.861) | 0.80 pmol·L-1 | 0.001 | 82.4 | 59.3 |
术后6个月 | 0.775(0.664~0.886) | 0.69 pmol·L-1 | <0.001 | 64.7 | 82.4 |
术后12个月 | 0.902(0.835~0.968) | 0.68 pmol·L-1 | <0.001 | 64.7 | 95.4 |
Tg | |||||
术前 | 0.741(0.606~0.876) | 62.08 μg·L-1 | 0.001 | 70.6 | 78.7 |
术后1个月 | 0.779(0.668~0.889) | 5.48 μg·L-1 | <0.001 | 76.5 | 67.6 |
术后3个月 | 0.799(0.698~0.889) | 2.24 μg·L-1 | <0.001 | 88.2 | 73.1 |
术后6个月 | 0.926(0.823~0.995) | 1.44 μg·L-1 | <0.001 | 88.2 | 86.1 |
术后12个月 | 0.953(0.891~0.996) | 1.02 μg·L-1 | <0.001 | 94.1 | 85.2 |
项目 | AUC(95%CI) | 最佳临界值 | P值 | 敏感性/% | 特异性/% |
TK1+Tg | |||||
术后1个月 | 0.780(0.627~0.934) | 0.298 | <0.001 | 70.6 | 92.6 |
术后3个月 | 0.885(0.812~0.959) | 0.340 | <0.001 | 88.2 | 73.1 |
术后6个月 | 0.934(0.855~0.999) | 0.211 | <0.001 | 94.1 | 81.5 |
术后12个月 | 0.964(0.933~0.995) | 0.213 | <0.001 | 94.1 | 87.0 |
项目 | β值 | 标准误 | Wald值 | P值 | OR值(95%CI) |
---|---|---|---|---|---|
T分期①(T1期与T2、T3期) | 1.621 | 0.341 | 22.586 | <0.001 | 5.060(2.593~9.875) |
术前Tg水平(<62.08 μg·L-1与≥62.08 μg·L-1) | 1.067 | 0.543 | 3.870 | 0.049 | 2.908(1.004~8.421) |
项目 | β值 | 标准误 | Wald值 | P值 | OR值(95%CI) |
---|---|---|---|---|---|
T分期①(T1期与T2、T3期) | 1.621 | 0.341 | 22.586 | <0.001 | 5.060(2.593~9.875) |
术前Tg水平(<62.08 μg·L-1与≥62.08 μg·L-1) | 1.067 | 0.543 | 3.870 | 0.049 | 2.908(1.004~8.421) |
[1] |
ZHANG Q, WANG Z, MENG X, et al. Predictors for central lymph node metastases in cN0 papillary thyroid microcarcinoma(mPTC):a retrospect analysis of 1 304 cases[J]. Asian J Surg, 2019, 42(4):571-576.
DOI URL |
[2] | 王晓庆, 魏玮, 魏玺, 等. 甲状腺乳头状癌的超声表现及其与颈部中央区淋巴结转移的关系[J]. 中华肿瘤杂志, 2018, 40(3):196-200. |
[3] |
VAISMAN F, CARVALHO D P, VAISMAN M. A new appraisal of iodine refractory thyroid cancer[J]. Endocr Relat Cancer, 2015, 22(6):R301-R310.
DOI URL |
[4] | 张勇, 董晓平, 魏耀宁, 等. 血清脂氧素A4和细胞质胸苷激酶1水平与食管鳞癌恶性生物学行为的相关性[J]. 中华实用诊断与治疗杂志, 2021, 35(7):692-695. |
[5] | 武鸿文, 梅艳, 王乔, 等. 血清MIP-1α、S-TK1对于甲状腺癌术后放射性131I治疗效果评估的临床价值[J]. 中国癌症杂志, 2021, 31(11):1088-1095. |
[6] |
HAUGEN B R, ALEXANDER E K, BIBLE K C, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer:the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer[J]. Thyroid, 2016, 26(1):1-133.
DOI URL |
[7] | 中华医学会核医学分会. 131I治疗分化型甲状腺癌指南(2021版)[J]. 中华核医学与分子影像杂志, 2021, 40(4):218-241. |
[8] |
SUN D, ZHENG X, HE X, et al. Prognostic value and dynamics of antithyroglobulin antibodies for differentiated thyroid carcinoma[J]. Biomark Med, 2020, 14(18):1683-1692.
DOI PMID |
[9] | 孙丹阳, 孟召伟, 谭建, 等. 年龄及甲状腺球蛋白抗体阳性水平对分化型甲状腺癌预后的影响[J]. 中华内分泌代谢杂志, 2021, 37(12):1068-1074. |
[10] | 卢承慧, 李娇, 刘新峰, 等. 首次131I治疗后淋巴结显影伴治疗前刺激性Tg阴性的分化型甲状腺癌的治疗反应及影响因素分析[J]. 中华核医学与分子影像杂志, 2020, 40(1):21-26. |
[11] | 中华人民共和国国家卫生健康委员会医政医管局. 甲状腺癌诊疗指南(2022年版)[J]. 中国实用外科杂志, 2022, 42(12):1343-1357. |
[12] |
ITO Y, MIYAUCHI A, ODA H, et al. Appropriateness of the revised Japanese guidelines' risk classification for the prognosis of papillary thyroid carcinoma:a retrospective analysisof 5 845 papillary thyroid carcinoma patients[J]. Endoc J, 2019, 66(2):127-134.
DOI URL |
[13] | RYU Y J, KANG S J, CHO J S, et al. Identifying risk factors of lateral lymph node recurrence in clinically node-negative papillary thyroid cancer[J]. Medicine(Baltimore), 2018, 97(51):e13435. |
[14] |
KEEGAN T H, RIES L A, BARR R D, et al. Comparison of cancer survival trends in the United States of adolescents and young adults with those in children and older adults[J]. Cancer, 2016, 122(7):1009-1016.
DOI PMID |
[15] |
CHOI W R, ROH J L, GONG G, et al. Multifocality of papillary thyroid carcinoma as a risk factor for disease recurrence[J]. Oral Oncol, 2019, 94:106-110.
DOI PMID |
[16] |
张晓英. 宫颈癌患者新辅助化疗前后TK1、ID-1水平变化与疗效的关系[J]. 检验医学, 2020, 35(2):108-111.
DOI |
[17] | 陈胜武, 刘言, 冯长生, 等. 胸苷激酶1和生存素在甲状腺癌及腺瘤组织的表达及其临床意义[J]. 中华实验外科杂志, 2019, 36(2):301-303. |
[18] |
PEIRIS A N, MEDLOCK D, GAVIN M. Thyroglobulin for monitoring for thyroid cancer recurrence[J]. JAMA, 2019, 321(12):1228.
DOI PMID |
[19] | 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)分化型甲状腺癌诊疗指南2021[J]. 肿瘤预防与治疗, 2021, 34(12):1164-1200. |
[20] | YANG X, LIANG J, LI T J, et al. Postoperative stimulated thyroglobulin level and recurrence risk stratification in differentiated thyroid cancer[J]. Chin Med J(Engl), 2015, 128(8):1058-1064. |
[1] | ZHANG Miaomiao, DUAN Dongkui, YU Chun, WANG Lina. Expression and prognostic assessment value of miR-924 and SLC1A5 in lung cancer tissues [J]. Laboratory Medicine, 2024, 39(1): 13-18. |
[2] | LAN Jun, LU Shuting, YANG Jianrui. Roles of serum IL-26 and IL-27 levels in patients with colorectal cancer [J]. Laboratory Medicine, 2024, 39(1): 7-12. |
[3] | WANG Yangshuyi, YE WEI, LIN Zhihao, HUANG Yuenuo, FANG Tao, DONG Xiaoting. Construction and validation of a model for pyroptosis-related features in lung adenocarcinoma [J]. Laboratory Medicine, 2023, 38(9): 833-841. |
[4] | ZHANG Han, LI Jun, LIU Xiaojiang, GUAN Yixiang. Role of serum albumin,interleukin-6 and ferritin combined determination in evaluating the functional prognosis of patients with spontaneous intracerebral hemorrhage [J]. Laboratory Medicine, 2023, 38(8): 713-718. |
[5] | ZHANG Na, NIU Weihua, SUN Yuanyuan, JIA Mei. CMV and EBV co-infection affecting patient prognosis after hematopoietic stem cell transplantation [J]. Laboratory Medicine, 2023, 38(8): 760-765. |
[6] | GUO Jie, LI Haixia, LI Xiaoyun. Correlation of preoperative RPR in peripheral blood with the prognosis of endometrial carcinoma patients [J]. Laboratory Medicine, 2023, 38(7): 675-679. |
[7] | WANG Tengfei, CHEN Shan, AN Hebing, ZHOU Lei. Expressions and roles of lncRNA CRNDE and miR-384 in peripheral blood of patients with acute leukemia [J]. Laboratory Medicine, 2023, 38(7): 686-691. |
[8] | YIN Ya, PAN Yuan, ZHOU Hongwei, SHEN Wei. Application progress of BNP and NT-proBNP in neonates [J]. Laboratory Medicine, 2023, 38(6): 518-523. |
[9] | ZHAO Jing, WANG Pei, LU Dandan, QI Dandan, LI Xuan. Expression levels of serum miR-4443 and TRAF4 in patients with hemorrhagic stroke [J]. Laboratory Medicine, 2023, 38(5): 413-418. |
[10] | SONG Shiwei, LI Jingwu, LIN Tao, LIU Zeyu, WANG Zhiqiang, SUN Weidong. Relationship between GPNMB and non-small cell lung cancer immune infiltration and prognosis [J]. Laboratory Medicine, 2023, 38(4): 347-351. |
[11] | LIU Junshan, GUO Mingfa, SUN Jia, SHI Lihuan, LIU Wei, DUAN Yongtao. Significance of minimal residual disease dynamic monitoring in the prognosis of acute B-lymphoblastic leukemia children with positive and negative ETV6/RUNX1 fusion genes [J]. Laboratory Medicine, 2023, 38(3): 209-214. |
[12] | CHEN Zhe, ZHANG Ling, LIU Jie, WANG Xia, ZHANG Bin, GAO Binghua. Relationship between serum miR-326 and chemotherapy sensitivity and prognosis in patients with treatment-related hematological malignancy [J]. Laboratory Medicine, 2023, 38(3): 251-256. |
[13] | YAN An, GUAN Xuhuizi, YU Tian, MIAO Gang, ZHAO Yanyang. Identification of a new susceptibility gene variant EPB41L4A rs1455421289 in Chinese PTC patients by WES [J]. Laboratory Medicine, 2023, 38(11): 1009-1014. |
[14] | GU Yi, WANG Rui, DENG Jie, YANG Yijing, ZHOU Wangke, CHEN Yunuo, CHEN Xiaosong, SHEN Wei, ZHOU Jingyi. Differential analysis and prognostic diagnostic value of inflammatory biomarkers in liver transplantation in patients with severe hepatitis and cirrhosis [J]. Laboratory Medicine, 2023, 38(11): 1044-1051. |
[15] | LIANG Weizhang, SHI Jianping, CHAI Lina, HAN Aizi. Relationship between serum cathepsin K and ADAMTS-7 with ventricular remodeling and prognosis in patients with chronic heart failure [J]. Laboratory Medicine, 2023, 38(10): 919-925. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||